Perhaps of greater relevance, RAS antagonists prevent diabetes and improve insulin sensitivity (reviewed in 18), whilst the RAS appears to play a role in the pathogenesis of the ‘metabolic syndrome’ (hypertension/impaired glucose tolerance/dyslipidaemia) 17, 88, 89. Here, INS is linked to diabetes mellitus.